New Directions in Cardiac Arrhythmia Management: Present Challenges and Future Solutions

Canadian Journal of Cardiology

Volumn 30, Issue 12, 2014, Pages S420-S430

  Nattel, Stanley ^a   Andrade, Jason ^a   Macle, Laurent ^a   Rivard, Lena ^a   Dyrda, Katia ^a   Mondesert, Blandine ^a   Khairy, Paul ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DRONEDARONE; PLACEBO; UNCLASSIFIED DRUG; VENTRICULAR ANTIARRHYTHMIC AGENT;

BIOLOGICAL THERAPY; CARDIAC IMPLANT; CARDIAC IMPLANTABLE ELECTRONIC DEVICE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MAGNETIC RESONANCE; DEVICE INFECTION; FAINTNESS; GENETICS; HEALTH ECONOMICS; HEART ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTABLE CARDIAC MONITOR; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MATHEMATICAL ANALYSIS; MEDICAL DEVICE COMPLICATION; MEDICAL DEVICE DISLODGE; MEDICAL DEVICE FRACTURE; MONITORING; PACEMAKER; REVIEW; RISK ASSESSMENT; SUDDEN CARDIAC DEATH; ARRHYTHMIAS, CARDIAC; FORECASTING; PROCEDURES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; BIOLOGICAL THERAPY; DEFIBRILLATORS, IMPLANTABLE; FORECASTING; HUMANS;

EID: 84922655656     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.09.027     Document Type: Review

References (80)

1. Go A.S., Mozaffarian D., Roger V.L., et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
2. Andrade J.A., Rivard L., Macle L. The past, the present and the future of cardiac ablation therapy. Can J Cardiol 2014, 30:S431-S441.
3. Sun B.C., Emond J.A., Camargo C.A. Direct medical costs of syncope-related hospitalizations in the United States. Am J Cardiol 2005, 95:668-671.
4. Ahmad Y., Lip G.Y., Lane D.A. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation as a cause of stroke. Can J Cardiol 2013, 29(7 suppl):S4-S13.
5. Borne R.T., Varosy P.D., Masoudi F.A. Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. JAMA Intern Med 2013, 173:859-865.
6. Myerberg R.J., Kessler K.M., Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation 1992, 85:I2-I10.
7. Dorman H.G., van Opstal J.M., Stevenhagen J., Scholten M.F. Conductor externalization of the Riata internal cardioverter defibrillator lead: tip of the iceberg? Report of three cases and review of literature. Europace 2012, 14:1161-1164.
8. Deckx S., Marynissen T., Rega F., et al. Predictors of 30-day and 1-year mortality after transvenous lead extraction: a single-centre experience. Europace 2014, 16:1218-1225.
9. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. NEngl J Med 1989, 321:406-412.
10. Waldo A.L., Camm A.J., deRuyter H., et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. Lancet 1996, 348:7-12.
11. Hohnloser S.H., Crijns H.J., van Eickels M., et al. ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. NEngl J Med 2009, 360:668-678.
12. Connolly S.J., Camm A.J., Halperin J.L., et al. Dronedarone in high-risk permanent atrial fibrillation. NEngl J Med 2011, 365:2268-2276.
13. Bennett M.T., Sanatani S., Chakrabarti S., Deyell M.W., Krahn A.D. Assessment of genetic causes of cardiac arrest. Can J Cardiol 2013, 29:100-110.
14. Tucker N.R., Ellinor P.T. Emerging directions in the genetics of atrial fibrillation. Circ Res 2014, 114:1469-1482.
15. Xiao L., Koopmann T.T., Ördög B., et al. Unique cardiac Purkinje fiber transient outward current β-subunit composition: a potential molecular link to idiopathic ventricular fibrillation. Circ Res 2013, 112:1310-1322.
16. Bezzina C.R., Barc J., Mizusawa Y., et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013, 45:1044-1049.
17. Ellinor P.T., Lunetta K.L., Albert C.M., et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet 2012, 44:670-675.
18. Sinner M.F., Tucker N.R., Lunetta K.L., et al. Integrating genetic, transcriptional, and functional analyses to identify five novel genes for atrial fibrillation. Circulation 2014, 130(15):1225-1235.
19. Churko J.M., Mantalas G.L., Snyder M.P., Wu J.C. Overview of high throughput sequencing technologies to elucidate molecular pathways in cardiovascular diseases. Circ Res 2013, 112:1613-1623.
20. Roden D.M. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?. Can J Cardiol 2013, 29:58-66.
21. Giada F., Gulizia M., Francese M., et al. Recurrent unexplained palpitations (RUP) study comparison of implantable loop recorder versus conventional diagnostic strategy. JAm Coll Cardiol 2007, 49:1951-1956.
22. Ziegler P.D., Glotzer T.V., Daoud E.G., et al. Detection of previously undiagnosed atrial fibrillation in patients with stroke risk factors and usefulness of continuous monitoring in primary stroke prevention. Am J Cardiol 2012, 110:1309-1314.
23. Cotter P.E., Martin P.J., Ring L., et al. Incidence of atrial fibrillation detected by implantable loop recorders in unexplained stroke. Neurology 2013, 80:1546-1550.
24. Verma A., Champagne J., Sapp J., et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 2013, 173:149-156.
25. Nattel S., Guasch E., Savelieva I., et al. Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014, 35:1448-1456.
26. Healey J.S., Connolly S.J., Gold M.R., et al. ASSERT Investigators. Subclinical atrial fibrillation and the risk of stroke. NEngl J Med 2012, 366:120-129.
27. Gulati A., Jabbour A., Ismail T.F., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 2013, 309:896-908.
28. Klem I., Weinsaft J.W., Bahnson T.D., et al. Assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. JAm Coll Cardiol 2012, 60:408-420.
29. Roes S.D., Borleffs C.J., van der Geest R.J., et al. Infarct tissue heterogeneity assessed with contrast-enhanced mri predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging 2009, 2:183-190.
30. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging 2012, 5:370-377.
31. Fallavollita J.A., Heavey B.M., Luisi A.J., et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. JAm Coll Cardiol 2014, 63:141-149.
32. Blankstein R., Osborne M., Naya M., et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. JAm Coll Cardiol 2014, 63:329-336.
33. Bisbal F, Fernandez-Armenta J, Berruezo A, Mont L, Brugada J. Use of MRI to guide electrophysiology procedures. Heart 2014; doi:. doi:10.1136/heartjnl-2013-304692.
34. Han F.T., Akoum N., Marrouche N. Value of magnetic resonance imaging in guiding atrial fibrillation management. Can J Cardiol 2013, 29:1194-1202.
35. Nazarian S., Bluemke D.A., Lardo A.C., et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation 2005, 112:2821-2825.
36. Nishida K., Datino T., Macle L., Nattel S. Atrial fibrillation ablation: translating basic mechanistic insights to the patient. JAm Coll Cardiol 2014, 64:823-831.
37. Lynn M.S., Barnard A.C., Holt J.H., Sheffield L.T. Aproposed method for the inverse problem in electrocardiology. Biophys J 1967, 7:925-945.
38. Shah A.J., Hocini M., Xhaet O., et al. Validation of novel 3-dimensional electrocardiographic mapping of atrial tachycardias by invasive mapping and ablation: a multicenter study. JAm Coll Cardiol 2013, 62:889-897.
39. Rudy Y. Noninvasive imaging of cardiac electrophysiology and arrhythmia. Ann N Y Acad Sci 2010, 1188:214-221.
40. Haissaguerre M., Hocini M., Denis A., et al. Driver domains in persistent atrial fibrillation. Circulation 2014, 130:530-538.
41. Narayan S.M., Baykaner T., Clopton P., et al. Ablation of rotor and focal sources reduces late recurrence of atrial fibrillation compared with trigger ablation alone: extended follow-up of the CONFIRM trial (conventional ablation for atrial fibrillation with or without focal impulse and rotor modulation). JAm Coll Cardiol 2014, 63:1761-1768.
42. Krummen D.E., Hayase J., Morris D.J., et al. Rotor stability separates sustained ventricular fibrillation from self-terminating episodes in humans. JAm Coll Cardiol 2014, 63:2712-2721.
43. Cutler M.J., Wan X., Laurita K.R., Hajjar R.J., Rosenbaum D.S. Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol 2009, 2:686-694.
44. Merchant F.M., Sayadi O., Moazzami K., Puppala D., Armoundas A.A. T-wave alternans as an arrhythmic risk stratifier: state of the art. Curr Cardiol Rep 2013, 15:398.
45. Cygankiewicz I. Heart rate turbulence. Prog Cardiovasc Dis 2013, 56:160-171.
46. Ashikaga H., Arevalo H., Vadakkumpadan F., et al. Feasibility of image-based simulation to estimate ablation target in human ventricular arrhythmia. Heart Rhythm 2013, 10:1109-1116.
47. McDowell K.S., Vadakkumpadan F., Blake R., et al. Mechanistic inquiry into the role of tissue remodeling in fibrotic lesions in human atrial fibrillation. Biophys J 2013, 104:2764-2773.
48. Andrade J.G., Connolly S.J., Dorian P., et al. Antiarrhythmic use from 1991 to 2007: insights from the Canadian Registry of Atrial Fibrillation (CARAF I and II). Heart Rhythm 2010, 7:1171-1177.
49. Iannone P., Haupt E., Flego G., et al. Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. JAMA Intern Med 2014, 174:625-629.
50. Nattel S., Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006, 5:1034-1049.
51. Dobrev D., Nattel S. New drugs for treatment of atrial fibrillation. Lancet 2010, 375:1212-1223.
52. Dobrev D., Carlsson L., Nattel S. Novel molecular targets for atrial fibrillation therapy. Nat Rev Drug Discov 2012, 11:275-291.
53. Wang Z., Fermini B., Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 1993, 73:1061-1076.
54. Cha T.J., Ehrlich J.R., Chartier D., Xiao L., Nattel S. Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation 2006, 113:1730-1737.
55. Courtemanche M., Ramirez R.J., Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: Insights from a mathematical model. Cardiovasc Res 1999, 42:477-489.
56. Makary S., Voigt N., Maguy A., et al. Differential protein kinase C isoform regulation and increased constitutive activity of acetylcholine-regulated potassium channels in atrial remodeling. Circ Res 2011, 109:1031-1043.
57. Burashnikov A., Di Diego J.M., Zygmunt A.C., Belardinelli L., Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation 2007, 116:1449-1457.
58. Comtois P., Sakabe M., Vigmond E.J., et al. Mechanisms of atrial fibrillation termination by rapidly unbinding sodium channel blockers. Am J Physiol 2008, 295:H1489-H1504.
59. Aguilar-Shardonofsky M., Nattel S., Comtois P. In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics. Biophys J 2012, 102:951-960.
60. Christmann W. On the treatment of paroxysmal tachycardia with a combination of quinidine and procaine amide. Med Klin 1961, 56:2004-2006.
61. Shimizu W., Aiba T., Kamakura S. Mechanisms of disease: current understanding and future challenges in Brugada syndrome. Nat Clin Pract Cardiovasc Med 2005, 2:408-414.
62. Grunnet M., Hansen R.S., Olesen S.P. hERG1 channel activators: a new anti-arrhythmic principle. Prog Biophys Mol Biol 2008, 98:347-362.
63. Li J, Maguy A, Duverger JE, etal. Induced KCNQ1 autoimmunity accelerates cardiac repolarization in rabbits: potential significance in arrhythmogenesis and antiarrhythmic therapy. Heart Rhythm. 2014; doi:. doi:10.1016/j.hrthm.2014.07.040.
64. +/calmodulin-dependent kinase II (CaMKII). Circulation 2012, 126:2125-2139.
65. Nattel S., Dobrev D. The multidimensional role of calcium in atrial fibrillation pathophysiology: mechanistic insights and therapeutic opportunities. Eur Heart J 2012, 33:1870-1877.
66. Nattel S., Bourne G., Talajic M. Insights into mechanisms of antiarrhythmic drug action from experimental models of atrial fibrillation. JCardiovasc Electrophysiol 1997, 8:469-480.
67. Iwasaki Y.K., Nishida K., Kato T., Nattel S. Atrial fibrillation pathophysiology: implications for management. Circulation 2011, 124:2264-2274.
68. Savelieva I., Kakouros N., Kourliouros A., Camm A.J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace 2011, 13:308-328.
69. Savelieva I., Kakouros N., Kourliouros A., Camm A.J. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace 2011, 13:610-625.
70. Fein A.S., Shvilkin A., Shah D., et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. JAm Coll Cardiol 2013, 62:300-305.
71. Abed H.S., Wittert G.A., Leong D.P., et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA 2013, 310:2050-2060.
72. Cho H.C., Marbán E. Biological therapies for cardiac arrhythmias: can genes and cells replace drugs and devices?. Circ Res 2010, 106:674-685.
73. Greenberg B., Yaroshinsky A., Zsebo K.M., et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). JACC Heart Fail 2014, 2:84-92.
74. Ploux S., Strik M., van Hunnik A., et al. Acute electrical and hemodynamic effects of multisite left ventricular pacing for cardiac resynchronization therapy in the dyssynchronous canine heart. Heart Rhythm 2014, 11:119-125.
75. Reddy V.Y., Knops R.E., Sperzel J., et al. Permanent leadless cardiac pacing: results of the LEADLESS trial. Circulation 2014, 129:1466-1471.
76. Auricchio A., Delnoy P.P., Regoli F., et al. First-in-man implantation of leadless ultrasound-based cardiac stimulation pacing system: novel endocardial left ventricular resynchronization therapy in heart failure patients. Europace 2013, 15:1191-1197.
77. Rhyner J., Knight B.P. The totally subcutaneous implantable defibrillator. Cardiol Clin 2014, 32:225-237.
78. Dagdeviren C., Yang B.D., Su Y., et al. Conformal piezoelectric energy harvesting and storage from motions of the heart, lung, and diaphragm. Proc Natl Acad Sci U S A 2014, 111:1927-1932.
79. Boriani G., Maniadakis N., Auricchio A., Vardas P. Health economics and outcomes research: a new challenge and field of action for the European Heart Rhythm Association. Europace 2010, 12:601-603.
80. Drummond M.F., Schwartz J.S., Jönsson B., et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008, 24:244-258.